AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18385498
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream, applied twice weekly for 16 weeks
Trial: 18385498
Drug: Placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice weekly for 16 weeks
Trial: 18385498
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream and Placebo
Trial: 16369855
Drug: Pre-emptive antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-emptive antibiotic treatment with ceftriaxone
Trial: 10211086
Drug: CAF (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF (400 mg/m2 cyclophosphamide, 25 mg/m2 doxorubicin, 500 mg/m2 5-fluorouracil)
Trial: 10211086
Drug: CMF (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (40 mg/m2 methotrexate, cyclophosphamide, 5-fluorouracil)
Trial: 8775024
Drug: No treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment, some types of mobilization and ice, amitriptyline (as control for tension-type headaches)
Trial: 2169216
Drug: Standard heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin, 5000 units subcutaneously three times a day
Trial: 2169216
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin 3500 anti-Xa units subcutaneously once daily
Trial: 28370327
Drug: 0.2 mL
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mL of 2% lidocaine with 1:80,000 epinephrine
Trial: 28370327
Drug: 0.6 mL
RxNorm normalized name: ethanol 0.6 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mL of 2% lidocaine with 1:80,000 epinephrine
Trial: 27678425
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (IT) with lovastatin (40 mg/d), niacin (2.5 g/d), and colestipol (20 g/d) from 1989 to 2004, followed by double therapy with simvastatin (40–80 mg/d) and niacin from 2005 to 2006 and triple therapy of ezetimibe 10 mg and simvastatin 40 to 80 mg/d plus niacin during 2007 to 2012
Trial: 22066583
Drug: Δ9-tetrahydrocannabinol (THC)
RxNorm normalized name: Δ9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Δ9-tetrahydrocannabinol (THC) inhalation
Trial: 717750
Drug: Enflurane inhalation
RxNorm normalized name: enflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enflurane inhalation anaesthesia
Trial: 29316908
Drug: Curamin® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curamin® (500 mg capsules containing 350 mg curcuminoids and 150 mg boswellic acid)
Trial: 29316908
Drug: CuraMed® (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CuraMed® (500 mg capsules containing 333 mg curcuminoids)
Trial: 23770843
Drug: Fish oil‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil‐based intravenous fat emulsion (FIFE) at 1 g/kg/d
Trial: 23770843
Drug: Soybean oil‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil‐based intravenous fat emulsion (SIFE)
Trial: 18608562
Drug: Fibruline Instant
RxNorm normalized name: Advanced Eye Relief Redness Instant Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibruline Instant (20 g/day)
Trial: 10630693
Drug: Steroids (methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids (methylprednisolone 1 g i.v. for three consecutive days at months 1, 3 and 5, plus oral prednisone 0.5 mg/kg every other day for six months) plus azathioprine 1.5 mg/kg/day for six months
Trial: 10630693
Drug: Steroids alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids alone with the same schedule
Trial: 9110940
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only (control)
Trial: 380910
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg amineptine daily for 6 weeks
Trial: 380910
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg maprotiline daily for 6 weeks
Trial: 31773582
Drug: Glucocorticoid (GC)
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (GC) replacement therapy
Trial: 31773582
Drug: Tailoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailoring of GC therapy
Trial: 31773582
Drug: General GC
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General GC replacement therapies
Trial: 27023419
Drug: Local acute
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local acute pain (capsaicin cream) (experiment 2)
Trial: 25123196
Drug: Caffeine exercise
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine exercise trial (EX+CAF, 2 × 3 mg/kg of caffeine 90 min before and 30 min after exercise)
Trial: 15028100
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy plus radical prostatectomy (study 1)
Trial: 15028100
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone (leuprorelin acetate with or without chlormadinone acetate, study 2)
Trial: 7661936
Drug: Standardised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised treatment consisting of 18 sessions in vivo exposure and response prevention
Trial: 22543884
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy with carboplatin and etoposide, and concurrent chest irradiation (34 SCLC patients)
Trial: 22543884
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy with cisplatin and gemcitabine, and radiotherapy (49 NSCLC patients)
Trial: 22543884
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment time of radiotherapy
Trial: 22543884
Drug: Mean oesophageal
RxNorm normalized name: DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean oesophageal dose
Trial: 20495585
Drug: Epidural methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural methylprednisolone (60 mg)
Trial: 20495585
Drug: Intrathecal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal midazolam (2 mg) with epidural methylprednisolone (60 mg)
Trial: 18554738
Drug: Camembert cheese
RxNorm normalized name: Penicillium camemberti
DrugBank: Penicillium camemberti (DB10809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camembert cheese (2x40 g/day for 4 weeks)
Trial: 15801934
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the morning
Trial: 15801934
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 800/200 mg administered once daily in the evening
Trial: 8445464
Drug: Placebo topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo topical paste
Trial: 3720307
Drug: Epinephrine plus
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine plus cortisol (5 mg/m2 . min) plus glucagon (3 mg/kg . min)
Trial: 31727306
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (CBT) for 9 weeks (n=25)
Trial: 27577862
Drug: Motivational Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Enhancement Therapy (MET) and Cognitive Behavioral Therapy (CBT)
Trial: 27577862
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) sessions (optional)
Trial: 21480005
Drug: Ortho All‐Flex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho All‐Flex diaphragm and Replens(®) lubricant gel
Trial: 21480005
Drug: Replens(®) lubricant
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replens(®) lubricant gel
Trial: 18648230
Drug: Propofol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (n = 6, 0.9 microg/ml target concentration)
Trial: 18648230
Drug: Thiopental at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental at sedative doses (n = 6, 3 microg/ml)
Trial: 17472024
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose perindopril 2 mg and indapamide 0.625 mg combination daily for 6 weeks
Trial: 17472024
Drug: Fixed low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed low-dose perindopril-indapamide
Trial: 14583174
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 70/30
Trial: 14583174
Drug: Biphasic human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic human insulin 70/30
Trial: 7624734
Drug: Standard 2-h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2-h oral glucose tolerance test (OGTT)
Trial: 6267648
Drug: IV injection
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of 5.0 mg delta 9-THC
Trial: 6267648
Drug: Smoking about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking about 13 mg delta 9-THC
Trial: 6267648
Drug: IV administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration
Trial: 31772079
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg daily for 10 days
Trial: 28336545
Drug: Protein- or
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein- or carbohydrate-based supplements during STRESS
Trial: 28336545
Drug: No supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No supplements during STRESS (control group)
Trial: 21684490
Drug: Strain-Counterstrain treatment
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strain-Counterstrain treatment combined with exercise therapy
Trial: 16443425
Drug: Methylphenidate 2
RxNorm normalized name: methylphenidate 25.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 2 x 10 mg/day
Trial: 15272642
Drug: Half-dose double-bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose double-bolus reteplase (2 x 5 IU) combined with abciximab
Trial: 15272642
Drug: Full-dose reteplase
RxNorm normalized name: reteplase
DrugBank: Reteplase (DB00015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Full-dose reteplase (2 x 10 IU)
Trial: 9249892
Drug: Hypnotic suggestions
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestions
Trial: 8142565
Drug: Mortality reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mortality reduction through early detection and treatment
Trial: 3061181
Drug: Telenzepine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine 3 mg nightly
Trial: 29211658
Drug: Letermovir (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir (480 mg per day or 240 mg per day in patients taking cyclosporine)
Trial: 10801251
Drug: Quinidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (4 mg/kg)
Trial: 9091708
Drug: DICpf pre‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DICpf pre‐ and postop. in combination with dexamethasone‐21‐dihydrogenphosphate 0.1% eyedrops (DEXA)
Trial: 9091708
Drug: Intraocular pressure
RxNorm normalized name: Brimonidine Tartrate 0.2% Ophthalmic drops, solution [Intraocular Pressure]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraocular pressure (IOP) management with carbachol 0.01% and dichlorphenamide (50 mg/d per os) until day 1 postoperatively
Trial: 1315469
Drug: Lyophilized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized inactivated hepatitis A vaccine (1.0 micrograms)
Trial: 1315469
Drug: Lyophilized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized inactivated hepatitis A vaccine (0.5 micrograms)
Trial: 1315469
Drug: Lyophilized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized inactivated hepatitis A vaccine (0.25 micrograms)
Trial: 1315469
Drug: Lyophilized inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized inactivated hepatitis A vaccine (all dosage groups)
Trial: 4006374
Drug: Disopyramide (D),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide (D), 1.5 and 2 mg/kg iv
Trial: 4006374
Drug: Dealkylated metabolite
RxNorm normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dealkylated metabolite (MND), 0.5 and 1.5 mg/kg iv
Trial: 22261200
Drug: Non-PPI gastrointestinal
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-PPI gastrointestinal drugs
Trial: 22261200
Drug: No gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No gastric therapy
Trial: 17686110
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray 110 microg once daily (n = 605)
Trial: 17686110
Drug: Vehicle placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo nasal spray (n = 201)
Trial: 15729552
Drug: Patient-provider relationship,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-provider relationship, facility setting, and information on diagnosis and treatment options
Trial: 12196372
Drug: CE (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE (cisplatin 20 mg/m(2) and etoposide 100 mg/m(2) on days 1-3)
Trial: 12196372
Drug: CCE (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCE (carboplatin 200 mg/m(2) on day 1, cisplatin 30 mg/m(2) on days 2-3, etoposide 100 mg/m(2) on days 1-3)
Trial: 7615269
Drug: 10 days'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days' treatment with metronidazole and eight weeks' treatment with colloidal bismuth subcitrate (CBS) (84 patients)
Trial: 7615269
Drug: 10 days'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days' treatment with metronidazole placebo and eight weeks with CBS (73 patients)
Trial: 7615269
Drug: open triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: open triple therapy (CBS 120 mg four times daily, amoxicillin 500 mg four times daily, and metronidazole 400 mg three times daily) given to patients with ulcer relapse
Trial: 25380152
Drug: 10g cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g cocoa (0, 80, 200, 500 and 800 mg cocoa flavonoids/day)
Trial: 25380152
Drug: 10g cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10g cocoa (80 mg cocoa flavonoids/day)
Trial: 23839178
Drug: 3mg Drospirenone/0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg Drospirenone/0.02 mg Ethinyl Estradiol
Trial: 14745876
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lipid complex (ABLC) 2.5 mg/kg intravenously 3 times weekly
Trial: 14745876
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AmB) 3 mg/kg 3 times weekly
Trial: 11673080
Drug: Cisplatin‐based combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin‐based combination chemotherapy
Trial: 8988721
Drug: 5-fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body weight/day for 7 days preoperatively
Trial: 29043567
Drug: S-1 chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 chemotherapy
Trial: 29043567
Drug: Taxane therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane therapies
Trial: 27895474
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (1.5 g/day for 10 weeks)
Trial: 20106684
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (Jarsin) administered t.i.d. for 15 days
Trial: 20106684
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered t.i.d. for 15 days
Trial: 18799995
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg x kg(‐1) body mass)
Trial: 11850269
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (AmBisome) at 2 mg/kg body weight
Trial: 11850269
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate at 0.6 mg/kg body weight
Trial: 7627761
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia with adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase with adrenaline)
Trial: 7627761
Drug: Retrobulbar anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrobulbar anesthesia without adrenaline (4 ml lidocaine 2% and 250 IU hyaluronidase without adrenaline)
Trial: 1957103
Drug: Slow-release oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release oral salbutamol (SRS) 8 mg b.d.
Trial: 7138719
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine 0.05 mg kg‐1
Trial: 7138719
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine 0.1 mg kg‐1
Trial: 30073390
Drug: hu14.18-IL2 immunocytokine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18-IL2 immunocytokine (IC) at 6 mg/m2/day i.v. on days 1, 2, and 3 of each 28-day course, 3 courses total.
Trial: 17714352
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol propionate magistral preparation
Trial: 16516075
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg clopidogrel pre-treatment for >=15 hours
Trial: 11004030
Drug: perflubron emulsion
RxNorm normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perflubron emulsion at 1.2 g PFC/kg
Trial: 11004030
Drug: perflubron emulsion
RxNorm normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: perflubron emulsion at 1.8 g PFC/kg
Trial: 11004030
Drug: saline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline (3 mL/kg) control
Trial: 23057417
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (IFN)
Trial: 23057417
Drug: No Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Interferon treatment
Trial: 15580451
Drug: 685-nm low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 685-nm low level laser therapy
Trial: 12380631
Drug: Naproxen 400
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 400 mg
Trial: 12380631
Drug: Naproxen 200
RxNorm normalized name: naproxen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 200 mg
Trial: 12380631
Drug: Naproxen 400
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 400 mg and 200 mg
Trial: 10428106
Drug: Two-drug combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug combinations of Zidovudine and Didanosine